This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Government Shutdown, Government Shmutdown
by Mark Vickery
Market indexes were ultimately unbothered by this latest federal government shutdown today, to say nothing of the negative private-sector payroll report this morning.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Stock Market News for Oct 1, 2025
by Zacks Equity Research
Wall Street closed higher on Tuesday, driven by healthcare stocks.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
by Aparajita Dutta
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Pfizer (PFE) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $23.6, denoting a -2.03% move from the preceding trading day.
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
by Zacks Equity Research
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
by Sundeep Ganoria
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
by Shaun Pruitt
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
by Kinjel Shah
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Company News for Sep 23, 2025
by Zacks Equity Research
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
by Kinjel Shah
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
by Ahan Chakraborty
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
by Zacks Equity Research
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
by Zacks Equity Research
Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
by Kinjel Shah
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
by Ahan Chakraborty
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
by Sundeep Ganoria
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
OLMA Stock Soars 47% in September So Far on Second PFE Deal
by Zacks Equity Research
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
by Kinjel Shah
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
by Ekta Bagri
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
Why Pfizer (PFE) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Pfizer (PFE) closed at $24.83, indicating a +1.04% shift from the previous trading day.
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
by Ekta Bagri
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.